BE905210A - Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. - Google Patents

Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. Download PDF

Info

Publication number
BE905210A
BE905210A BE2/61025A BE2061025A BE905210A BE 905210 A BE905210 A BE 905210A BE 2/61025 A BE2/61025 A BE 2/61025A BE 2061025 A BE2061025 A BE 2061025A BE 905210 A BE905210 A BE 905210A
Authority
BE
Belgium
Prior art keywords
sep
coenzyme
pharmaceutical preparations
creatine phosphate
muscle
Prior art date
Application number
BE2/61025A
Other languages
English (en)
Dutch (nl)
Original Assignee
Seuref Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seuref Ag filed Critical Seuref Ag
Publication of BE905210A publication Critical patent/BE905210A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2/61025A 1985-08-06 1986-08-04 Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. BE905210A (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH3362/85A CH666183A5 (it) 1985-08-06 1985-08-06 Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.

Publications (1)

Publication Number Publication Date
BE905210A true BE905210A (nl) 1986-12-01

Family

ID=4254335

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2/61025A BE905210A (nl) 1985-08-06 1986-08-04 Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme.

Country Status (8)

Country Link
JP (1) JPS6253924A (ja)
BE (1) BE905210A (ja)
CH (1) CH666183A5 (ja)
DE (1) DE3625433A1 (ja)
FR (1) FR2586352B1 (ja)
GB (1) GB2178661B (ja)
IT (1) IT1213319B (ja)
NL (1) NL8601979A (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19537494A1 (de) * 1995-09-25 1997-03-27 Desitin Arzneimittel Gmbh Kreatin zum Schutz von neuralem Gewebe

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1407782A4 (en) * 2001-06-28 2004-10-20 Takeda Chemical Industries Ltd DRUGS FOR THE PREVENTION / TREATMENT OF FUNCTIONAL ORGAN DISORDERS AND ORGAN DYSFUNCTION
DE202023001978U1 (de) 2023-09-20 2023-09-29 Penta Phi Eg Formulierung umfassend Coenzym Q10 und Kreatin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19537494A1 (de) * 1995-09-25 1997-03-27 Desitin Arzneimittel Gmbh Kreatin zum Schutz von neuralem Gewebe

Also Published As

Publication number Publication date
FR2586352A1 (fr) 1987-02-27
FR2586352B1 (fr) 1992-05-29
IT1213319B (it) 1989-12-20
GB2178661A (en) 1987-02-18
IT8621394A0 (it) 1986-08-01
GB8618589D0 (en) 1986-09-10
GB2178661B (en) 1989-08-31
CH666183A5 (it) 1988-07-15
JPS6354690B2 (ja) 1988-10-28
JPS6253924A (ja) 1987-03-09
NL8601979A (nl) 1987-03-02
DE3625433A1 (de) 1987-02-19

Similar Documents

Publication Publication Date Title
DE3855120T2 (de) The use of AICA riboside or AICA ribotide for the preparation of a medicament against heart attack or stroke in patients with atherosclerosis
US4693995A (en) Pharmaceutical composition for the treatment of acute myocardial ischemia
JP2004506657A (ja) 天然および合成ｈｃａのバイオアベイラブルな組成物
EP0786993B1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and their use in the treatment of metabolic and cardiovascular disorders
BG99164A (bg) Антиисхемично лекарствено средство
US5843996A (en) Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution
BE905210A (nl) Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme.
US4451485A (en) Treatment of cardio-vascular diseases with 3-(2,2,2-trimethylhydrazinium) propionate dihydrate
JP2007536256A (ja) 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法
RU2096034C1 (ru) Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
Falcone et al. Cardiotoxicity of doxorubicin: effects of 21-aminosteroids
ES2240656T3 (es) Compuesto cosmetico contenido ribosa.
Tripathi et al. Effect of�-Tocopherol Pretreatment on Infarct Size following 90 Minutes of Ischemia and 4 Hours of Reperfusion in Dogs
Röth et al. Free radical mediated injuries after coronary artery occlusion
Levett et al. Effects of dimethyl sulfoxide on systemic and cerebral hemodynamic variables in the ischemic canine myocardium
WO2023218364A1 (en) Anti-aging and anti-inflammatory compositions comprising nicotinamide mononucleotide and reservatrol and uses thereof
RU2292885C2 (ru) Антиаритмическое лекарственное средство "тиодарон"
JPH0526766B2 (ja)
EA003470B1 (ru) Фармацевтическая композиция тгп и ингибитора апф
HU228959B1 (en) Use of specific dose of fondaparinux sodium for preparation of medicament for treatment of acs
Clark Uses of creatine phosphate and creatine supplementation for the athlete
RU2146933C1 (ru) Способ профилактики и лечения ишемии миокарда при коронароинвазивных вмешательствах
RU2664668C1 (ru) Антиаритмическое лекарственное средство
RU2153880C1 (ru) Общеукрепляющее средство для профилактики и лечения заболеваний сердечно-сосудистой системы
JPH03115220A (ja) 非心臓由来の不整脈防止薬

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: SEUREF A.G.

Effective date: 19930831